Leukotac (inolimomab) / Mediolanum Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   40 News 
  • ||||||||||  Leukotac (inolimomab) / Mediolanum Pharma
    Journal:  Bacteroides thetaiotaomicron uses a widespread extracellular DNase to promote bile-dependent biofilm formation. (Pubmed Central) -  Mar 11, 2022   
    We determined that bile-dependent biofilm formation involves the production of the DNase BT3563 or its homologs, degrading extracellular DNA (eDNA) in several B. thetaiotaomicron strains. Our study therefore shows that, although biofilm matrix eDNA provides a biofilm-promoting scaffold in many studied Firmicutes and Proteobacteria, BT3563-mediated eDNA degradation is required to form B. thetaiotaomicron biofilm in the presence of bile.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Review, Journal, Adverse events:  Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review. (Pubmed Central) -  Dec 22, 2020   
    Reported infections per patient were lower under extracorporeal photopheresis (ECP) for aGvHD (0.267 infections per patient over 6 months) relative to any of the therapies studied (ranging from 0.853 infections per patient per 6 months under etanercept up to 1.998 infections per patient on inolimomab). The reported incidence of infectious AEs in aGvHD and grade 3-5 AEs in cGvHD was lower on ECP compared with pharmaceutical management.
  • ||||||||||  Leukotac (inolimomab) / ElsaLys
    Optical coherence tomography grading of retinopathy associated with bardet-biedl syndrome (Room 241 (Level 2)) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1669;    
    Each grade represents a change in retinal architecture (in a continuing spectrum of progression of retinal degeneration) that is easily identified and maybe used clinically to extrapolate an assessment of visual function (based on published evidence of OCT features – visual functional correlations). Furthermore, this grading system may help in accurate objective monitoring of disease progression and also serve as a useful objective endpoint in clinical trials for BBS.
  • ||||||||||  Leukotac (inolimomab) / ElsaLys
    Clinical, Journal:  A pathogenic homozygous variant of the BBS10 gene in a patient with Bardet Biedl syndrome (Pubmed Central) -  Apr 18, 2019   
    As the Bardet-Biedl syndrome is a rare disease, it is challenging to interpret its pleiotropism and gene/allelic heterogeneity. Its confirmation by molecular tests allows an adequate approach, follow-up, and genetic counseling of the patient and the family.
  • ||||||||||  Leukotac (inolimomab) / Mediolanum Pharma
    Spatial and temporal dynamics of respiratory syncytial virus infections in New South Wales and Western Australia () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1467;    
    Each subtype, regardless of location, was dominated by a single genotype (RSV-A/ON1-like and RSV-B/BA10-like).  Our WGS analysis identified a number of features of RSV epidemiology including i) the co-circulation of both subtypes RSV-A and RSV-B; ii) a single genotype for each subtype predominates each season; iii) multiple distinct sub-lineages of each genotype co-circulate and are associated with regional and local clustering/outbreaks and iv) viral mixing is apparent despite geographic clustering.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Zinbryta (daclizumab) / Biogen, AbbVie, Leukotac (inolimomab) / Mediolanum Pharma
    Biomarker, Retrospective data, Review, Journal:  Steroids vs. steroids plus additional agent in frontline treatment of acute graft-versus-host disease: a systematic review and meta-analysis of randomized trials. (Pubmed Central) -  Feb 18, 2018   
    The additional agent(s) used in the experimental arm(s) were higher-dose steroids, antithymocyte globulin, infliximab, anti-interleukin-2 receptor antibody (daclizumab and BT563), CD5-specific immunotoxin, and mycophenolate mofetil...In conclusion, these results argue against the value of augmented generic immunosuppression beyond steroids for frontline treatment of aGvHD and emphasize the importance of developing alternative strategies. Novel forms of immunomodulation and targeted therapies against non-immune-related pathways may enhance the efficacy of steroids in this setting and early predictive and prognostic biomarkers can help identify the subgroup of patients that would likely need treatments other than (or in addition to) generic immunosuppression.